Top Cited Papers
Open Access
Abstract
Growth factors, including recombinant human bone morphogenetic protein‐2 (rhBMP2), have been clinically utilised for large bone augmentation with good outcomes. Nevertheless, long‐term healing, swelling, safety concerns, and high cost limit their use. Exosomes, nanoscale extracellular vesicles, have emerged as promising regenerative alternatives. This study assessed the osteogenic potential of periodontal‐specific exosomes (Px) on bone marrow mesenchymal stem cells (BMSCs) compared to rhBMP2. Px were morphologically characterised by TEM and quantified via BCA assay. BMSCs were treated with Px at 1:10, 1:50, and 1:100 dilutions (100, 20, and 10 μg/mL) and compared to rhBMP2 (100 ng/mL). Px uptake was evaluated using PKH26 labeling. Functional assays included viability, migration, alkaline phosphatase (ALP) activity, alizarin red (ARS) mineralization, collagen, osteocalcin secretion, and RT‐PCR analysis of osteogenic genes. Px exhibited spheroidal to cup‐shaped morphology and internalisation in BMSCs up to 18 days. Compared to rhBMP2, Px promoted viability (1.14‐fold), migration (1.78‐fold) up to 1.14 and 1.78‐fold, ALP (1.48‐, 4.11‐fold), ARS (1.43‐, 14.71‐fold), collagen (1.40‐, 3.58‐fold), and osteocalcin (1.86‐, 5.2‐fold). Gene expression demonstrated significant upregulation of ALP (1.73‐fold), RUNX2 (1.70‐fold), OCN (1.36‐fold), and OPN (1.35‐fold). Overall, Px significantly enhanced BMSC osteogenesis compared to rhBMP2, highlighting their potential as a cell‐free nanotherapeutic in bone tissue engineering.

This publication has 53 references indexed in Scilit: